Details for Patent: 7,807,689
✉ Email this page to a colleague
Which drugs does patent 7,807,689 protect, and when does it expire?
Patent 7,807,689 protects KAZANO, NESINA, and OSENI, and is included in three NDAs.
This patent has fifty-eight patent family members in thirty-five countries.
Summary for Patent: 7,807,689
| Title: | Dipeptidyl peptidase inhibitors |
| Abstract: | The present invention provides a compound of the formula: |
| Inventor(s): | Zhiyuan Zhang, Bruce J. Elder, Paul K. Isbester, Grant J. Palmer, Luckner G. Ulysse |
| Assignee: | Takeda Pharmaceutical Co Ltd |
| Application Number: | US11/080,992 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,807,689 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Delivery; Dosage form; |
Drugs Protected by US Patent 7,807,689
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-002 | Jan 25, 2013 | RX | Yes | Yes | 7,807,689 | ⤷ Start Trial | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Start Trial | ||
| Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-001 | Jan 25, 2013 | RX | Yes | No | 7,807,689 | ⤷ Start Trial | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Start Trial | ||
| Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-001 | Jan 25, 2013 | RX | Yes | No | 7,807,689 | ⤷ Start Trial | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Start Trial | ||
| Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-002 | Jan 25, 2013 | RX | Yes | No | 7,807,689 | ⤷ Start Trial | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Start Trial | ||
| Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-003 | Jan 25, 2013 | RX | Yes | Yes | 7,807,689 | ⤷ Start Trial | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,807,689
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1586571 | ⤷ Start Trial | C300640 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1586571 | ⤷ Start Trial | CA 2014 00011 | Denmark | ⤷ Start Trial |
| European Patent Office | 1586571 | ⤷ Start Trial | PA2014011 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1586571 | ⤷ Start Trial | 14C0013 | France | ⤷ Start Trial |
| European Patent Office | 1586571 | ⤷ Start Trial | 172 5006-2014 | Slovakia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
